Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn's disease: a propensity score-adjusted real-world study.

Int J Clin Pharm · 2026 · PMC13176074 · PMID 41739407

Europe PMC DOI

hedged sentences

0.1470

closest p · 2.9× alpha

0.1470

boldest claim

The sentences

did not reach statistical significanceP = 0.147not close (p > 0.1)

However, this difference did not reach statistical significance (Fisher’s exact test, P = 0.147).

also in 74,032 other papers

a numerical trendno p-value reported

In the propensity score-matched cohort, we observed a numerical trend toward higher median IFX trough levels and a lower incidence of ADAs in the combination group compared with IFX monotherapy.

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.